$SELLAS Life Sciences Group Inc.(SLS)$ It's July, and we're still waiting for the 80th event.
Most people see a delay. I see what happens when an immunotherapy keeps patients alive long enough that events stop occurring on schedule.
GPS isn't CAR-T. It doesn't engineer cells—it trains your own immune system to recognize WT1 and keeps expanding T-cell responses over time. That's exactly why the FDA approved unlimited dosing in REGAL.
No 80th event. Unlimited dosing. Growing immunotherapy spotlight. Change-in-control filings.
The pieces keep lining up. If patients weren't living longer, this trial would've been over months ago.
The delay isn't the story... the data is.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
